Zobrazeno 1 - 10
of 991
pro vyhledávání: '"H Segal"'
Autor:
Spencer R. Rosario, Mark D. Long, Shanmuga Chilakapati, Eduardo Cortes Gomez, Sebastiano Battaglia, Prashant K. Singh, Jianmin Wang, Katy Wang, Kristopher Attwood, Suzanne M. Hess, AJ Robert McGray, Kunle Odunsi, Brahm H. Segal, Gyorgy Paragh, Song Liu, Jennifer A. Wargo, Emese Zsiros
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-13 (2024)
Abstract Recurrent ovarian cancer patients, especially those resistant to platinum, lack effective curative treatments. To address this, we conducted a phase 2 clinical trial (NCT02853318) combining pembrolizumab with bevacizumab, to increase T cell
Externí odkaz:
https://doaj.org/article/70dcee0bb9064927b3d9ece85a9d7ca9
Autor:
Neil H. Segal, Ignacio Melero, Victor Moreno, Neeltje Steeghs, Aurelien Marabelle, Kristoffer Rohrberg, Maria E. Rodriguez-Ruiz, Joseph P. Eder, Cathy Eng, Gulam A. Manji, Daniel Waterkamp, Barbara Leutgeb, Said Bouseida, Nick Flinn, Meghna Das Thakur, Markus C. Elze, Hartmut Koeppen, Candice Jamois, Meret Martin-Facklam, Christopher H. Lieu, Emiliano Calvo, Luis Paz-Ares, Josep Tabernero, Guillem Argilés
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-14 (2024)
Abstract Cibisatamab is a bispecific antibody-based construct targeting carcinoembryonic antigen (CEA) on tumour cells and CD3 epsilon chain as a T-cell engager. Here we evaluated cibisatamab for advanced CEA-positive solid tumours in two open-label
Externí odkaz:
https://doaj.org/article/c7ab25df143a4df7a0b711f295ef7d2c
Autor:
Melissa Van Norden, Zackary Falls, Sapan Mandloi, Brahm H. Segal, Bora E. Baysal, Ram Samudrala, Peter L. Elkin
Publikováno v:
Communications Biology, Vol 7, Iss 1, Pp 1-10 (2024)
Abstract Intra-organism biodiversity is thought to arise from epigenetic modification of constituent genes and post-translational modifications of translated proteins. Here, we show that post-transcriptional modifications, like RNA editing, may also
Externí odkaz:
https://doaj.org/article/b55971b1c57b43fbb50a94f454ea9ef3
Autor:
Paolo A. Ascierto, Antonio Avallone, Carlo Bifulco, Sergio Bracarda, Joshua D. Brody, Leisha A. Emens, Robert L. Ferris, Silvia C. Formenti, Omid Hamid, Douglas B. Johnson, Tomas Kirchhoff, Christopher A. Klebanoff, Gregory B. Lesinski, Anne Monette, Bart Neyns, Kunle Odunsi, Chrystal M. Paulos, Daniel J. Powell, Katayoun Rezvani, Brahm H. Segal, Nathan Singh, Ryan J. Sullivan, Bernard A. Fox, Igor Puzanov
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-21 (2023)
Abstract The discovery and development of novel treatments that harness the patient’s immune system and prevent immune escape has dramatically improved outcomes for patients across cancer types. However, not all patients respond to immunotherapy, a
Externí odkaz:
https://doaj.org/article/627c0bedba0a40d4b9dd41c55b9dde62
Autor:
Dirk Schadendorf, Ignacio Melero, Robert L Ferris, William Sharfman, Satyendra Suryawanshi, Jaclyn Neely, Fabrice Barlesi, Dung T Le, Jason J Luke, Patrick A Ott, Tina Cascone, Nikhil I Khushalani, Abanti Sanyal, Scott Ely, Manish R Sharma, Deanne Lathers, James L Holloway, Rasika Suryawanshi, Neil H Segal
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 3 (2024)
Background Resistance to immune checkpoint inhibitors and targeted treatments for cancer is common; thus, novel immunotherapy agents are needed. Urelumab is a monoclonal antibody agonist that binds to CD137 receptors expressed on T cells. Here, we re
Externí odkaz:
https://doaj.org/article/6310bf50e26a495fafc831096d8929f8
Autor:
Chen Li, Ana Ferro, Shivani K. Mhatre, Danny Lu, Marcus Lawrance, Xiao Li, Shi Li, Simon Allen, Jayesh Desai, Marwan Fakih, Michael Cecchini, Katrina S. Pedersen, Tae You Kim, Irmarie Reyes-Rivera, Neil H. Segal, Christelle Lenain
Publikováno v:
Communications Medicine, Vol 2, Iss 1, Pp 1-8 (2022)
Li et al. report outcomes from the atezolizumab/isatuximab arm of the phase Ib/II MORPHEUS-CRC trial in patients with metastatic colorectal cancer. In addition, the authors leverage historical control data from the phase III IMblaze370 study to provi
Externí odkaz:
https://doaj.org/article/a2d8a6d7f97440f4b6e89b19aac1153c
Autor:
Surekha Annadanam, Gunjan Garg, Angela Fagerlin, Corey Powell, Emily Chen, Jonathan H. Segal, Akinlolu Ojo, Julie Wright Nunes
Publikováno v:
Kidney Medicine, Vol 5, Iss 4, Pp 100602- (2023)
Rationale & Objective: Multidisciplinary chronic kidney disease (CKD) care has been associated with improved clinical outcomes in comparison to general nephrology care. However, there is little research examining the impact of multidisciplinary care
Externí odkaz:
https://doaj.org/article/101947d68e334e9886cf26ad5d55e441
Autor:
Neha Mehta, Jennifer M. Harrington, Meghan A. Wallace, Jillianna M. Wasiura, Carey-Ann D. Burnham, Katherine M. Mullin, Brahm H. Segal, Nikolaos G. Almyroudis
Publikováno v:
Antimicrobial Stewardship & Healthcare Epidemiology, Vol 3 (2023)
Ribotyping was performed on Clostridioides difficile isolates from patients with malignancies. Thirty-one (27.9%) isolates from 111 episodes of colitis were recovered representing 14 ribotypes with 25 (80.6%) belonging to 6 ribotypes (014/020, 1/VPI/
Externí odkaz:
https://doaj.org/article/54e6dba26bad419ea689dd59f7f8039b
Autor:
Takayoshi Yamauchi, Toshifumi Hoki, Takaaki Oba, Vaibhav Jain, Hongbin Chen, Kristopher Attwood, Sebastiano Battaglia, Saby George, Gurkamal Chatta, Igor Puzanov, Carl Morrison, Kunle Odunsi, Brahm H. Segal, Grace K. Dy, Marc S. Ernstoff, Fumito Ito
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
There is an urgent need to discover blood-based biomarkers to predict response to immune checkpoint inhibitors (ICI). Here the authors show that effective ICI therapy correlates with increased frequency of circulating CX3CR1+CD8+ T cells in preclinic
Externí odkaz:
https://doaj.org/article/5ad9763c2d134ba4b389bb215a94772a
Autor:
Emad Y. Alqassim, Shraddha Sharma, A. N. M. Nazmul H. Khan, Tiffany R. Emmons, Eduardo Cortes Gomez, Abdulrahman Alahmari, Kelly L. Singel, Jaron Mark, Bruce A. Davidson, A. J. Robert McGray, Qian Liu, Brian D. Lichty, Kirsten B. Moysich, Jianmin Wang, Kunle Odunsi, Brahm H. Segal, Bora E. Baysal
Publikováno v:
Communications Biology, Vol 4, Iss 1, Pp 1-11 (2021)
Alqassim et al find that RNA editing, known to be induced by IFN-1 in macrophages by the enzyme APOBEC3A, is required for the transcriptional, pro-inflammatory and metabolic responses that drive M1 macrophage polarization. APOBEC3A-mediated editing i
Externí odkaz:
https://doaj.org/article/8289df36f80e4288872e7c05d2e770f3